A computer implemented method for a data sharing system to share healthcare data from a healthcare data provider with a healthcare data processing application. The method includes identifying one or more healthcare data processor applications, generating and displaying selectable options of the one or more data processor applications at a healthcare data provider, obtaining a selection of the one or more data processor applications from the healthcare data provider, obtaining a data provider/application-specific encryption keyset corresponding to each selected healthcare data processor application, the keyset comprising a private key and a public key, retaining the private key of the data provider/application-specific keyset with a trusted component of the healthcare data provider, and sharing the public key of the data provider/application-specific keyset with the corresponding selected healthcare data processor application.
G16H 40/20 - ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the management or administration of healthcare resources or facilities, e.g. managing hospital staff or surgery rooms
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
The present invention relates to diagnostic test and technology. In particular, the present invention relates to a method for determining an analyte suspected to be present in a sample comprising contacting said sample with a sensor element comprising an anchor layer which is present on a solid support, a first binding agent which is capable of specifically binding to the analyte, which is anchored in the anchor layer and which comprises at least one magnetic label, wherein said at least one magnetic label is located within the anchor layer, a second binding agent which is capable of specifically binding to the analyte when bound to the first binding agent and which is immobilized on the solid support, and a magnetic tunnel junction in functional proximity to the second binding agent which generates a signal elicited in proximity to the at least one magnetic label of the first binding agent, for a time and under conditions which allow for specific binding of the analyte suspected to be present in the sample to the first binding agent and specific binding of the second binding agent to the analyte bound to the first binding agent and detecting the formation the complex of first binding agent, analyte and second binding agent based on the signal which is generated by the magnetic tunnel junction whereby the analyte is determined. Moreover, provided is a device for determining an analyte suspected to be present in a sample and the use thereof for determining an analyte suspected to be present in a sample in said sample. Moreover, the present invention contemplates a kit for determining an analyte suspected to be present in a sample.
The present invention relates to a method of determining an analyte in a sample by mass spectrometry (MS), the method comprising (a) admixing a pre-determined amount of internal calibrator to said sample, wherein said internal calibrator comprises at least two non-identical isotopologues of the analyte at predetermined amounts; (b) determining MS signals of ions generated from said analyte (analyte signal) and from said at least two isotopologues (isotopologue signals); (c) providing a calibration based on the analyte signal and the isotopologue signals determined in step (b); and (d) determining said analyte based on the calibration provided in step (c). Further, the present invention relates to devices, systems, and uses related thereto.
The present invention relates to chemical probes for the improved detection of cysteine in a test sample, preferably an aqueous test sample, as well as respective uses and kits.
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
C07C 259/06 - Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
The present invention relates to reagents which are suitable to be used in mass spectrometry as well as methods of mass spectrometric determination of analyte molecules using said reagents.
C07D 249/06 - 1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
C07D 203/04 - Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 403/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
A healthcare computer system, the computer system comprising a communications module, a string generation module, a one-way function module and an anonymised data generation module. The communications module is configured to receive one or more healthcare data packets, each healthcare data packet including: data pertaining to one or more medical analytical tests performed on a sample; a sample identifier, identifying the sample; and a timestamp, indicating when the analytical test(s) was performed. The string generation module is configured to generate a string based on the sample identifier and the timestamp. The one-way function module is configured to apply a one-way function to the generated string to generate an anonymised sample identifier. The anonymised data generation module is configured to generate an anonymised healthcare data packet including the data pertaining to the one or more medical analytical tests and the anonymised sample identifier.
G16H 10/40 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
A healthcare data management system for managing processing capacity in a healthcare data management system. The healthcare data management system includes: one or more processing pipelines connected to one or more of the medical devices and configured to receive medical data therefrom, wherein each processing pipeline comprises a plurality of processing stages arranged in series and configured to perform respective operations on the received healthcare data, wherein each processing stage is implemented on a stateless atomic processing unit; a healthcare middleware is configured to receive processed data therefrom and to provide the processed data to a healthcare information management system; a performance management unit is configured to monitor a performance of the or each processing pipeline and adjust a number of stateless atomic processing units implementing a given processing stage within a given processing pipeline based on the monitored performance.
G16H 10/40 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
G06F 9/48 - Program initiating; Program switching, e.g. by interrupt
G16H 40/20 - ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the management or administration of healthcare resources or facilities, e.g. managing hospital staff or surgery rooms
8.
MONITORING DEVICE FOR MONITORING A SAMPLE HANDLING SYSTEM
A monitoring device for monitoring a sample handling system comprising:
a sliding unit comprising a sliding surface, wherein the sliding unit is configured for sliding over a sample transport device of the sample handling system; and
an imaging streaming unit comprising s camera, wherein the camera is configured for capturing a plurality of images, wherein the imaging streaming unit comprises an imaging communication interface for providing the plurality of captured images to a transport control system of the sample handling system.
A monitoring device for monitoring a sample handling system comprising:
a sliding unit comprising a sliding surface, wherein the sliding unit is configured for sliding over a sample transport device of the sample handling system; and
an imaging streaming unit comprising s camera, wherein the camera is configured for capturing a plurality of images, wherein the imaging streaming unit comprises an imaging communication interface for providing the plurality of captured images to a transport control system of the sample handling system.
Further disclosed is a transport control system for controlling transport of a plurality of sample container holders of a sample handling system, a sample handling system for handling a plurality of samples, a method for identifying an obstacle, a method for determining a distance between the obstacle and a monitoring device and a method for controlling a monitoring device and computer programs and computer-readable storage media for performing the methods.
G01N 35/00 - Automatic analysis not limited to methods or materials provided for in any single one of groups ; Handling materials therefor
G01N 35/02 - Automatic analysis not limited to methods or materials provided for in any single one of groups ; Handling materials therefor using a plurality of sample containers moved by a conveyor system past one or more treatment or analysis stations
G06T 7/55 - Depth or shape recovery from multiple images
G06V 10/82 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using neural networks
Embodiments of the present disclosure relate to automated validation of medical data. Some embodiments of the present disclosure provide a method for medical data validation. The method comprises obtaining target medical data generated in a medical test and obtaining a machine learning model for validating medical data. The machine learning model represents an association between the medical data and validation results, the validation results indicating information about predetermined actions to be performed on the medical data. The method further comprises determining a target validation result for the target medical data by applying the target medical data to the machine learning model, the target validation result indicating information about a target action selected from the predetermined actions to be performed on the target medical data. Through the solution, it is possible to achieve automated medical data validation with high accuracy and efficiency as well as reduced manual efforts.
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
G16H 15/00 - ICT specially adapted for medical reports, e.g. generation or transmission thereof
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
Fusion polypeptides are disclosed which are substrates for Kutzneria albida transglutaminase. The fusion polypeptides comprise one or more FKBP chaperone(s) and a target polypeptide. Each of these elements is separated from the neighboring element by a linker amino acid sequence. It was found that inserting glutamic acid containing transglutaminase recognition motifs into the linker amino acid chains is advantageous. Subsequent labeling reactions catalyzed by the transglutaminase surprisingly provide labeled fusion polypeptides have superior properties when compared with chemically random-labeled fusion polypeptides of similar design. Assays and kits are provided for in vitro detection of target antibodies in samples.
The disclosure concerns methods for the detection of an analyte in a sample by electro-chemiluminescence using new reagent compositions. New reagent compositions, reagent kits for measuring electrochemiluminscence (ECL) and electrochemiluminescence detection methods using the new reagent compositions are disclosed. In particular, the disclosure relates to the use of novel combinations of compounds which can be used in said measurements to provide improved assay performance.
G01N 33/543 - Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
C07F 15/00 - Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic System
G01N 21/66 - Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light electrically excited, e.g. electroluminescence
SAMPLE VESSEL CLOSURE METHOD, MOVABLE CAP GRIPPER AND SAMPLE VESSEL CLOSURE SYSTEM FOR AUTOMATICALLY CLOSING AN OPEN END OF A SAMPLE VESSEL WITH A CLOSURE CAP
A method for automatically closing an open end of a sample vessel with a closure cap, including, inter alia, the steps of grasping an upper part of the closure cap at its outer circumference by means of a cap gripper with at least two gripper fingers comprising respective top thrust ledges extending at least in part over a recess provided by a lateral gripping face, and of pushing the closure cap into the open end of the sample vessel by means of the top thrust ledge. In addition, a respective movable cap gripper for automatically closing the open end of the sample vessel with the closure cap as well as a respective sample vessel closure system is provided.
B65B 7/28 - Closing semi-rigid or rigid containers or receptacles not deformed by, or not taking-up shape of, contents, e.g. boxes or cartons by applying separate preformed closures, e.g. lids, covers
G01N 35/00 - Automatic analysis not limited to methods or materials provided for in any single one of groups ; Handling materials therefor
21.
PROCESSING OF TEST SAMPLES IN A LABORATORY SETTING
A computer-implemented method of automatically locating and processing test sample(s) from a patient within a laboratory setting 100 is disclosed. The method comprises determining that a test sample has not been processed by any device in the laboratory and the test sample is still within a time period of processing, performing inquiry of historical data of previous non-located test samples maintained in a database for possible locations of non-located test sample, and notifying laboratory operator of a location with a highest probability of test sample location based on the historical data.
G16H 10/40 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
22.
CONSOLIDATION AND PRIORITIZATION OF PATIENT CRITICAL NOTIFICATIONS
A computer-implemented method of consolidating critical information for a patient in a laboratory is presented. The method comprises selecting a patient to monitor from a population of patients associated with the laboratory, extracting information for the patient from a plurality of laboratory sources in the laboratory, determining if the extracted patient information is critical to care of the patient, and outputting the extracted patient critical information to a single display dashboard for display to a laboratory operator.
G16H 10/40 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
G16H 15/00 - ICT specially adapted for medical reports, e.g. generation or transmission thereof
G16H 40/20 - ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the management or administration of healthcare resources or facilities, e.g. managing hospital staff or surgery rooms
23.
PSP94 AS BLOOD BIOMARKER FOR THE NON-INVASIVE DIAGNOSIS OF ENDOMETRIOSIS
The present invention relates to methods of assessing whether a patient has endometriosis or is at risk of developing endometriosis and in particular early stages to methods of selecting a patient for therapy and to methods for monitoring disease progression in a patient suffering from endometriosis or being treated for endometriosis by determining the amount or concentration of PSP94 in a sample of the patient, and comparing the determined amount or concentration to a reference.
A laboratory apparatus for use in a laboratory sample handling system, wherein the apparatus comprises a cap waste disposal catcher, wherein the catcher is designed to catch a laboratory cap removed from a laboratory sample container containing a laboratory sample, and an electric field generator, wherein the generator is designed to generate an electric field to attract a residue of the sample released by the cap to the catcher.
G01N 35/02 - Automatic analysis not limited to methods or materials provided for in any single one of groups ; Handling materials therefor using a plurality of sample containers moved by a conveyor system past one or more treatment or analysis stations
G01N 35/04 - Automatic analysis not limited to methods or materials provided for in any single one of groups ; Handling materials therefor using a plurality of sample containers moved by a conveyor system past one or more treatment or analysis stations - Details of the conveyor system
The present disclosure relates to a computer implemented method of managing sample processing priorities in a diagnostic laboratory comprising at least one sample processing device connected to a host system. The method comprises generating a communication message between the host system and the at least one sample processing device related to a sample processing order received in association with a sample, the message comprising one of at least two priority identifiers (R, S) indicative of respective sample processing priorities from lower priority to higher priority according to the received sample processing order. The method further comprises identifying the sample by the at least one sample processing device and processing the sample by the at least one sample processing device according to the sample processing priority (S, R) in the message. In case of receiving a subsequent request for change of sample processing priority for the sample from a lower priority to a higher priority after transmission of the message and before the sample is processed, the method comprises changing the message and processing the sample as a higher priority sample instead of as a lower priority sample, wherein changing the message comprises changing the lower priority identifier (R) to an identifier (CS) indicative of a change of priority but different from an equivalent higher priority identifier (S) in order to maintain the sample and the sample processing order uniquely identifiable and traceable by both the host system and the at least one sample processing device. A respective system for managing sample processing priorities is herein also disclosed.
G16H 10/40 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
G06F 9/48 - Program initiating; Program switching, e.g. by interrupt
The present invention relates to a clinical diagnostic system, a method for determining the presence or level of at least one analyte of interest in a biological sample, a kit and the uses thereof for efficiently and/or robust detection of an analyte of interest.
The present invention relates to monoclonal antibodies binding to the nucleocapsid protein of SARS-CoV-2 virus, nucleic acids encoding said antibody, host cells producing the same, compositions and kits comprising said antibodies, as well as methods of detecting SARS-CoV-2 virus in a sample comprising using said antibodies.
A method for determining system resistance of at least one power supply of a handheld medical device, the method including: a) generating at least one excitation voltage signal, wherein the excitation voltage signal comprises at least one direct current (DC) voltage signal, wherein the excitation voltage signal has a fast transition DC flank of 20 ns or less; b) applying the excitation voltage signal to at least one reference resistor having a predetermined or pre-defined resistance value, wherein the reference resistor is arranged in series with the power supply; c) measuring a response signal of the power supply; d) determining a signal flank from the response signal and determining an ohmic signal portion from one or both of shape and height of the signal flank; and e) determining the system resistance of the power supply from the ohmic signal portion.
G01R 27/14 - Measuring resistance by measuring current or voltage obtained from a reference source
G01R 31/36 - Arrangements for testing, measuring or monitoring the electrical condition of accumulators or electric batteries, e.g. capacity or state of charge [SoC]
The disclosure relates to a sample container holding and/or transporting device having an aperture with a longitudinal axis, which aperture is configured for receiving a sample container, wherein a biasing structure is provided in the aperture, which comprises a plurality of elastically deflectable nubs, wherein the nubs are distributed spatially discrete along the longitudinal axis of the aperture. The disclosure further relates to a use of a structure having nubs as a biasing structure in a sample container holding and/or transporting device, and to a laboratory automation system comprising a sample container holding and/or transporting device.
The present disclosure relates to a method of preparing a magnetic particle having a polymer matrix (P) and at least one magnetic core (M), preferably at least two magnetic cores (M), wherein the polymer matrix (P) comprises at least one hypercrosslinked polymer, wherein the method comprises (i) providing at least one magnetic core (M), preferably at least two magnetic cores (M), (ii) providing polymer precursor molecules, (iii) polymerizing the polymer precursor molecules according to (ii) in the presence of the at least one magnetic core (M), thereby forming a particle comprising the at least one magnetic core (M). Further, the present disclosure relates to particles obtained or obtainable by this method as well as to the use of these particles. In a further aspect, the disclosure relates to a method for determining at least one analyte in a fluid sample having the step of contacting of the magnetic particle with a fluid sample having or suspected of having the at least one analyte.
B01J 20/28 - Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties
The present invention relates to bacterial pilus protein complex FimGt-DsF stabilized protein complexes for producing phagemids or filamentous phages, and methods for use of these.
A column device for an automatic analyser. The automatic analyzer comprises a high performance liquid chromatography (HPLC) module. The HPLC module comprises a fixation device configured to automatically fix and release a chromatographic column. The column device comprises a column jacket and a capillary. The capillary comprises predetermined dimensions and is disposed within the column jacket. The column device is configured to be installed at the HPLC module using the fixation device. Further, an automatic analyzer is disclosed.
A gripping apparatus for gripping a sample container comprising: a gripper body comprising a gripper actuator; at least two gripper fingers each comprising a gripping surface, wherein at least one of the gripper fingers is movably coupled to the gripper body, and wherein the gripping apparatus is designed for gripping a sample container with the gripping surfaces of the at least two gripper fingers by moving the at least one movable gripper finger; and characterized in that the gripping apparatus comprises at least one elastically mounted contacting surface for elastically contacting a sample container about to be gripped by the gripping apparatus.
CIRCULATING TOTAL-NT-PROBNP (GLYCOSYLATED AND UNGLYCOSYLATED NT-PROBNP) AND ITS RATIO WITH NT-PROBNP (UNGLYCOSYLATED NT-PROBNP) IN THE ASSESSMENT OF ATRIAL FIBRILLATION
The present invention relates to a method for diagnosing atrial fibrillation in a subject, said method comprising the steps of a) determining the amount of total NT-proBNP in sample from the subject, b) determining the amount of unglycosylated NT-proBNP in a sample from the subject, c) calculating a score of the amounts determined in steps a) and b), d) comparing the calculated score with a reference score, and e) diagnosing atrial fibrillation in a subject.
The present disclosure relates to a laboratory data management system 100 comprising a data source layer 10 comprising at least one laboratory device 11, 12, 13, 14, 15 as a data source, a data adapter layer 20 comprising at least one data source agent 21, 22, 23, 24, 25 configured to obtain data from the at least one data source and to convert the data from a data source format to a data-source independent format, a consumer layer 30 configured for installation and/or execution of consumer application software 31, 32, 33, 34, and a data management layer 40 between the data adapter layer 20 and the consumer layer 30. The data management layer 40 comprises a data storage 50 configured to store data 1-n converted by the at least one data source agent 21, 22, 23, 24, 25, at least one data manager 41, 42, 43, 44 programmed to execute instructions from the consumer application software 31, 32, 33, 34, which when executed cause the at least one data manager 41, 42, 43, 44 to select application-specific data in the data storage 50 and to make them accessible to a consumer via the consumer application software 31, 32, 33, 34 in a consumer format. The data adapter layer 20 and the data management layer 40 are arranged in a laboratory gateway 60 connected to the data-source layer 10 and to the consumer layer 30.
G16H 10/40 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
G16H 40/40 - ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the management of medical equipment or devices, e.g. scheduling maintenance or upgrades
36.
PROGNOSTIC VALUE OF BIOMARKERS IN PATIENTS WITH NON-SMALL CELL LUNG CANCER HAVING STABLE DISEASE
The present invention relates to an in vitro method for assessing the risk of non-small cell lung carcinoma (NSCLC) disease progression for a subject classified to have stable disease under an ongoing NSCLC treatment regime. The method involves determining the level of CYFRA 21-1 and/or the level of CA 125 in a sample obtained from the subject; and comparing (i) the determined level of CYFRA 21-1 to a CYFRA 21-1 cut-off level, (ii) the determined level of CA 125 to a CA 125 cut-off level, or (iii) a score taking into account the determined level of CYFRA 21-1 and/or the determined level of CA 125 to a cut-off score. The method of the invention further allows for assessing whether the subject responds to the ongoing treatment and/or whether the treatment regime should be maintained or modified. The invention also provides for corresponding uses, computer-implemented methods and computer program products.
A method for processing data of an analytical instrument for analyzing biological samples is presented. The method comprises receiving instrument data from the analytical instrument at a data processing module communicatively connected with the analytical instrument, generating metadata from the received instrument data at the data processing module, applying a first encryption to the instrument data at the data processing module, applying a second encryption to the generated metadata at the data processing module, and transmitting the encrypted metadata and encrypted instrument data to a remote server. The remote server and the data processing module are communicatively connected. The method also comprises removing the second encryption from the metadata at the remote server and forwarding the instrument data encrypted by the first encryption from the remote server to a management system of the analytical instrument.
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
G16H 40/67 - ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
G16H 40/20 - ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the management or administration of healthcare resources or facilities, e.g. managing hospital staff or surgery rooms
H04W 12/033 - Protecting confidentiality, e.g. by encryption of the user plane, e.g. user’s traffic
H04L 67/561 - Adding application-functional data or data for application control, e.g. adding metadata
H04L 67/565 - Conversion or adaptation of application format or content
The present invention relates to a method for assessing whether a subject has experienced one or more silent infarcts in a subject, said method comprising a) determining the amount of the biomarker ESM-1 in a sample from the subject, b) comparing the amount determined in step a) to a reference, and c) assessing whether a subject has experienced one or more silent infarcts. The present invention further relates to a method for predicting silent infarcts and/or cognitive decline, and methods for assessing and monitoring of the extent of silent small and large noncortical and cortical infarcts in a subject. Further encompassed by the present invention are the corresponding uses.
The present invention relates to an antibody or an antigen binding fragment thereof that specifically binds to α-1,6-core-fucosylated prostate specific antigen (PSA) and partial sequences thereof comprising the α-1,6-core-fucose residue. The antibodies and antigen binding fragments significantly discriminate between core-fucosylated PSA or core-fucosylated PSA partial sequences and other glycosylated PSA species and partial sequences thereof lacking the core-fucose residue, including aglycosylated PSA, as well as core-fucosylated glycan in other contexts. The present invention further relates to nucleic acid molecules encoding the light chain variable region or the heavy chain variable region of the antibody of the invention, as well as vectors comprising said nucleic acid molecules. The invention also relates to a host cell comprising the vector(s) of the invention, as well as to methods for the production of an antibody or antigen binding fragment of the invention comprising culturing the host cell of the invention under suitable conditions and isolating the antibody produced. Furthermore, the present invention relates to an antibody obtainable by the method of the invention, to a composition comprising at least one of the antibody or antigen binding fragment of the invention, the nucleic acid molecule of the invention, the vector of the invention, the host cell of the invention or the antibody produced by the method of the invention. The present invention also relates to the use of an antibody or antigen binding fragment of the invention for detecting and discriminating core-fucosylated PSA or core-fucosylated partial sequences thereof in biological samples.
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
G01N 33/574 - Immunoassay; Biospecific binding assay; Materials therefor for cancer
An automatic analyzer is capable of reducing the time required for a series of maintenance operations in that the user’s maintenance work is linked to the device driving so that the maintenance work proceeds in the order of the maintenance work tools. An automatic analyzer includes a plurality of processing units for processing a specimen: an agitation mechanism, a reagent dispensing mechanism, a mixer, an incubator, and a specimen dispensing mechanism. A control unit controls a processing unit, an analysis unit, and a display unit and causes the display unit to display a plurality of maintenance work tools used for maintenance work performed by the operator on the plurality of processing units and to display the maintenance work contents of the plurality of processing units that continuously use one of the plurality of maintenance work tools, selected by the operator via the display unit.
G01N 35/02 - Automatic analysis not limited to methods or materials provided for in any single one of groups ; Handling materials therefor using a plurality of sample containers moved by a conveyor system past one or more treatment or analysis stations
G01N 35/10 - Devices for transferring samples to, in, or from, the analysis apparatus, e.g. suction devices, injection devices
G01N 35/00 - Automatic analysis not limited to methods or materials provided for in any single one of groups ; Handling materials therefor
41.
DETECTION OF AN ANALYTE OF INTEREST BY NANOESI MASS SPECTROMETRY
The present invention relates to a method, a diagnostic system, a kit and the use thereof for efficiently detection of an analyte of interest by nanoESI mass spectrometry.
The present invention relates to a method for providing a verified analyte measurement of a sample with a chromatography mass spectrometer device, said method comprising the following steps: a) admixing an interferent monitoring compound and, optionally an internal standard, to the sample; b) determining a chromatogram of the sample by acquiring a plurality of data points for signal intensities over time for said interferent monitoring compound, said analyte, and optionally said internal standard; and c) comparing a property of an interferent monitoring compound peak to a property of an internal standard peak and/or to a property of an analyte peak; and to methods and systems related thereto.
G01N 33/96 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood or serum control standard
G01N 30/88 - Integrated analysis systems specially adapted therefor, not covered by a single one of groups
G01N 33/74 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones
The present invention relates to a method for detecting and/or quantifying an analyte in a sample using mass spectrometry. The method of the invention comprises: extracting the analyte from the sample using solid phase extraction (SPE) so as to obtain an SPE extract comprising the analyte, concentrating the analyte, said concentrating comprising evaporating solvent from the SPE-extract; and detecting and/or quantifying the analyte in the sample using mass spectrometry.
The present invention relates to a method for detecting and/or quantifying one or more steroids using mass spectrometry, said steroids comprising at least one 11-oxygenated steroids. The method of the invention comprises (i) extracting the one or more steroids from the sample using solid phase extraction (SPE) so as to obtain an SPE extract comprising the one or more steroids; (ii) concentrating the one or more steroids, said concentrating comprising evaporating solvent from the SPE-extract; and (iii) detecting or quantifying the one or more steroids in the sample using mass spectrometry.
The present invention relates to a method for determining at least one analyte of interest. The present invention further relates to a kit, a complex, a method to synthesize a complex and the use thereof for detecting the analyte of interest in the sample.
A method for optimizing at least one parameter setting of at least one mass spectrometry device (110) operating at unit resolution is disclosed. The method comprises the following steps:
a) determining at least one analyte detection window for detecting an analyte of interest with the mass spectrometry device (110), wherein the analyte detection window is defined by a central mass to charge ratio value of the analyte and a predefined width, wherein the central mass to charge ratio value of the analyte is set to a theoretical mass to charge ratio value of the analyte of interest having more than one decimal place and/or a mass to charge ratio value of the analyte of interest determined by a high resolution mass spectrometry measurement having more than one decimal place;
b) determining at least one internal standard detection window for detecting an internal standard substance with the mass spectrometry device (110), wherein the internal standard detection window is defined by a central mass to charge ratio value of the internal standard substance and the pre-defined width, wherein the central mass to charge ratio value of the internal standard substance is set to a mass to charge ratio value of the internal standard substance calculated relative to the analyte of interest and having more than one decimal place and/or to a mass to charge ratio value of the internal standard substance determined by a high resolution mass spectrometry measurement having more than one decimal place.
The present invention relates to compounds which are suitable to be used in mass spectrometry as well as methods of mass spectrometric determination of analyte molecules using said compounds.
A Reagent container cap (116) is adapted to being mounted to a reagent container and to being adjustable, at least after an initial opening of the cap (116), between an opened state and a closed state, wherein the reagent container cap (116) defines a cap interior space (109) and has a cap opening (116o) allowing access to the cap interior space (109) from above when the cap (116) is in the opened state; and wherein, in the closed state of the cap (116), the cap interior space (109) is open only towards a bottom side (116b), wherein the reagent container cap (116) comprises a main portion (116m) and an insert portion (116i) that are fixedly connected to each other and made from different materials, wherein, when the cap (116) is in the closed state, the cap interior space (109) comprises a region (109t) which is delimited circumferentially and towards the upper side of this region completely and exclusively by surfaces of the insert portion (116i).
A reaction vessel for a diagnostic analyzer comprising a plurality of processing stations. The reaction vessel comprises at least one sensor configured to measure at least one physical parameter associated with at least one of the processing stations of the diagnostic analyzer when disposed at the at least one of the processing stations, a memory configured to at least temporarily store at least one measurement value indicating the physical parameter provided by the sensor, a processing unit configured to control the sensor and to output measurement data including the measurement value from the memory, an interface configured to provide communication of the processing unit with an external electronic device, a power source configured to supply electric power to the sensor, the processing unit and the memory. The reaction vessel defines an internal volume. The sensor, the processing unit, the memory and the interface are arranged within the internal volume.
An automated method of calibrating a sensor located in a flow-through sensor path and requiring at least one oxygenated calibration fluid for calibration comprises transporting a predefined amount of deoxygenated calibration fluid from a fluid supply into a fluidic line between a fluid-selection valve and the sensor path, transporting ambient air into the fluidic line before and after transporting the calibration fluid forming an isolated plug of calibration fluid between zones of ambient air, oscillating the calibration fluid plug back and forth within a predefined length of the fluidic line causing reciprocating fluid film tailing along the inner walls of the fluidic line, and facilitating oxygenation of the calibration fluid via oxygen uptake by the fluid film from the ambient air in the fluidic line, and transporting the oxygenated calibration fluid into the sensor path at a position where the sensor is located and calibrating the sensor.
The present invention relates to a method, a diagnostic system, a dopand and the use thereof for the enhancement of detection of an analyte of interest by Cross Spray ESI mass spectrometry.
The present invention relates to a method for assessing whether a subject has experienced one or more silent infarcts in a subject, said method comprising a) determining the amount of IGFBP7 in a sample from the subject, b) comparing the amount determined in step a) to a reference, and c) assessing whether a subject has experienced one or more silent infarcts. The present invention further relates to a method for predicting silent infarcts and/or cognitive decline, and methods for assessing and monitoring of the extent of silent small and large noncortical and cortical infarcts in a subject. Further encompassed by the present invention are the corresponding uses.
The present invention relates to an in vitro method for assessing cholangiocarcinoma in a patient sample, comprising the steps of: a) determining the level of tissue inhibitor of metalloproteinase-1 (TIMP1) in the patient sample, wherein the patient sample is selected from a group consisting of serum, plasma and whole blood sample from an individual, b) comparing the level of TIMP1 determined in step (a) with a reference level of TIMP1, and c) assessing cholangiocarcinoma in the patient sample by comparing the level determined in step (a) to the reference level of TIMP1, wherein an increased level of TIMP1 compared to the reference level of TIMP1 is indicative for cholangiocarcinoma in the patient sample. Further, the present invention relates to an in vitro method for assessing cholangiocarcinoma comprising TIMP1 and MMP2, the use of TIMP1 and optionally MMP2 in the in vitro assessment of CCA, and a kit for performing the said methods.
The present disclosure refers to a sensor assembly for an IVD analyzer, the sensor comprising two opposite substrates with at least one fluidic conduit for receiving a sample. The electrodes of different types of electrochemical sensors are arranged on the two opposite substrates facing the at least one fluidic conduit for coming in contact with the sample and determining sample parameters, wherein the counter electrodes and the reference electrodes are formed on one substrate and the working electrodes are formed on the opposite substrate. This achieves optimal sensor-working conditions in terms of a homogeneous and symmetrical electric field density and enables a sensor assembly with simpler geometry and smaller size.
G01N 27/06 - Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating impedance by investigating resistance of a liquid
G01N 33/487 - Physical analysis of biological material of liquid biological material
55.
MULTIMARKER PANEL FOR THE ASSESSMENT OF SILENT BRAIN INFARCTS AND COGNITIVE DECLINE
The present invention relates to a method for assessing whether a subject has experienced one or more silent infarcts in a subject, said method comprising a) determining the amounts of the biomarkers Osteopontin, cardiac Troponin, a natriuretic peptide and FABP-3 in a sample from the subject, b) comparing the amounts determined in step a) to references, and c) assessing whether a subject has experienced one or more silent infarcts. The present invention further relates to a method for predicting silent infarcts and/or cognitive decline, and methods for assessing and monitoring of the extent of silent small and large noncortical and cortical infarcts in a subject. Further encompassed by the present invention are the corresponding uses.
A computer-implemented method of providing user guidance for laboratory issue resolution within a laboratory system is presented. The method comprises monitoring activity by a user within a laboratory setting of the laboratory system by a user guidance system, detecting a laboratory issue within the laboratory system, retrieving by the user guidance system a preferred resolution to the detected laboratory issue and typical time to perform preferred solution from a database, notifying the user to the laboratory issue, detecting a non-preferred issue resolution for the laboratory issue being performed by the user, displaying the user guidance system to the user, wherein the user guidance system provides the retrieved preferred resolution for the laboratory issue to the user, resolving the laboratory issue by the user using the user guidance system, and removing or updating the display of the user guidance system following the resolution of the laboratory issue.
A handheld diagnostic device, specifically for point-of-care applications. The handheld diagnostic device comprises at least one diagnostic measurement unit configured for performing at least one diagnostic measurement, the diagnostic measurement unit comprising at least one test element port for determining at least one diagnostic parameter of at least one patient by using at least one diagnostic test element; at least one camera configured for capturing at least one image of at least one wound of the patient; and at least one control unit, the control unit being configured for controlling the diagnostic measurement and for controlling the capturing of the image of the wound, wherein the control unit is further configured for storing at least one measurement result of the diagnostic measurement and the at least one image in at least one database record of the patient. A diagnostic system and a diagnostic method are further disclosed.
The present invention relates to a method for determining the presence or level of an analyte of interest and the use thereof. Further, present invention relates to an analytical system, a sampling tube and the use of the sampling tube and a nucleophilic derivatization reagent.
The present invention relates to a method for determining at least one analyte of interest. The present invention further relates to a sample element, a device, a kit and the use thereof for determining at least one analyte of interest.
A monitoring device for monitoring an electric motor, specifically of a laboratory system, is disclosed. The monitoring device comprises at least one receiving unit configured for receiving information on at least one amount of acceleration energy required for accelerating the electric motor from at least one first motion state to at least one second motion state and at least one evaluation unit configured for evaluating the information on the amount of acceleration energy and for determining at least one item of information on a wearing status of the electric motor. The acceleration energy comprises an acceleration energy which is at least one of dissipated, recuperated or released when decelerating the electric motor from a rotating motion state to a stationary state. Further, a laboratory system, a method of monitoring an electric motor, a method of operating a laboratory system, computer programs and computer-readable storage media are disclosed.
A laboratory system, comprising: at least one rack comprising retainers, wherein the rack is adapted to carry laboratory sample containers inserted in the retainers, a handling device, wherein the handling device is adapted to insert sample containers in the retainers or remove containers from the retainers being placed at a processing position depending on location information indicating the location of the rack being placed at the processing position relative to the handling device, a plurality of teaching devices, wherein a respective teaching device is insertable into a retainer of the rack, and wherein at least two teaching devices are inserted into a corresponding retainer of the rack being placed at the processing position, and a location information calculating device, wherein the calculating device is adapted to calculate the location information of the rack being placed at the processing position depending on the location of the at least two teaching devices.
A system and method for treatment of biological samples is disclosed. In some embodiments, an automated biological sample staining system (100), comprising at least one microfluidic reagent applicator (118); at least one bulk fluid applicator (116); at least one fluid aspirator; at least one sample substrate holder; at least one relative motion system; and a control system (102) that is programmed to execute at least one staining protocol on a sample mounted on a substrate that is held in the at least one sample substrate holder.
The present invention relates to a method and the use thereof for for determining the level of Vitamin D and metabolites thereof. Further, it is an object of the present invention to provide a kit and the use thereof for determining the level of Vitamin D and metabolites thereof.
A computer-implemented method for detecting at least one interference and/or at least one artefact in at least one chromatogram determined by at least one mass spectrometry device (110) is proposed. The chromatogram comprises a plurality of raw data points. The method comprises the following steps:
a) retrieving the at least one chromatogram by at least one processing device (126);
b) applying at least one peak fit modelling to the chromatogram by using the processing device (126);
c) determining information about residuals of the raw data points by using the processing device (126);
d) detecting the at least one interference and/or the at least one artefact by using the processing device (126) by comparing the determined information about the residuals with at least one pre-determined threshold, wherein, if the determined information about the residuals exceed the pre-determined threshold, the at least one interference and/or the at least one artefact is detected.
An electrochemiluminescence method of detecting an analyte in a liquid sample and a corresponding analysis system. An analyte in a liquid sample is detected by first providing a receptacle containing a fluid comprising protein coated magnetic microparticles to a stirring unit. Stirring of the fluid is necessary since the density of the microparticles is usually higher than the density of the buffer fluid. Thus the microparticles tend to deposit on the bottom of the receptacle leading to an aggregation of the microparticles because of weak interactions. To obtain representative measurements a homogeneous distribution of the microparticles in the buffer fluid is necessary to ensure a constant concentration of microparticles for each analysis cycle. It is further necessary to provide disaggregation of the microparticles, which is also realized by stirring the fluid. Stirring is conducted with a rotational frequency that is adapted to the amount of fluid to be stirred.
G01N 33/543 - Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
G01N 21/66 - Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light electrically excited, e.g. electroluminescence
G01N 33/58 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
G01N 35/00 - Automatic analysis not limited to methods or materials provided for in any single one of groups ; Handling materials therefor
G01N 21/69 - Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light electrically excited, e.g. electroluminescence specially adapted for fluids
Embodiments of the present disclosure relate to method and system for diagnostic analyzing. Some embodiments of the present disclosure provide a diagnostic analyzing system. The diagnostic analyzing system comprises one or more analyzer instruments and a monitoring system, e.g. a quality control monitoring system. The one or more analyzer instruments designed for providing an analytical testing result, which is to be validated by the monitoring system using a validation algorithm. Moreover, the monitoring system may re-train the validation algorithm when a difference level between a live data set and a first training data set is greater than a threshold. Through the solution, it is possible to improve the accuracy of the validation algorithm.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
68.
METHOD FOR DETECTING AND REPORTING AN OPERATION ERROR IN AN IN-VITRO DIAGNOSTIC SYSTEM AND AN IN-VITRO DIAGNOSTIC SYSTEM
The present disclosure refers to a method for detecting and reporting an operation error in an in-vitro diagnostic system (1) for determining a sample of a bodily fluid, comprising: providing a plurality of sample vessels (2) each containing a sample of a bodily fluid; and providing a plurality of functional modules (3), comprising an analysis device (4) configured to determine the sample, a handling system (5) configured to handle the plurality of sample vessels (2), and an automation track (6) provided by the handling system (5) and configured to transport the plurality of sample vessels (2) to the analysis device (4). The method further comprises: providing an operation control device (7) connected to at least one of the functional modules (3) and configured to control operation of the at least one functional module (3), and comprising one or more data processors (8), wherein an application software is running on the one or more data processors (8) for controlling operation of the at least one functional module (3); controlling operation of the at least one functional module (3) by the operation control device (7); and detecting and reporting an operation error by an error detecting and reporting device (9), comprising: detecting the operating error for the operation of at least one of the plurality of functional modules (3) and the operation control device (7), providing error data indicative of the operation error, receiving a user input through a user interface (10) after detecting the operation error, providing labelling data in response to receiving the user input, the labelling data being indicative of information related to the operating error in addition to the error data, providing error report data comprising the error data and the labelling data, and transmitting the error report data to an error repository (11) remotely located with respect to both the plurality of functional modules (3) and the operation control device (7); receiving the error report data in a machine learning process running in a data processing device connected to the error repository (11); processing the error report data by the machine learning process in the data processing device; providing a application software update for the application software in response to the processing of the error report data by the machine learning process in the data processing device; providing the application software update to the operation control device (7); and controlling operation of the at least one functional module (3) by the operation control device (7) comprising running the application software including the application software update. Further, an in-vitro diagnostic system for determining a sample of a bodily fluid is provided.
The present disclosure refers to a computer-implemented training system for user-interactive training of a plurality of in-vitro diagnostic (IVD) methods performable in an IVD laboratory system, comprising: one or more data processors; a memory device connected to the one or more data processors; a user interface provided with an output device having a display device and an input device configured to receive user input; and one or more software applications running on the one or more data processors and having a plurality of application modules. The plurality of application modules is further configured to control, in response to receiving user input, output of a plurality of views of the IVD laboratory system through the display device according to view output control data indicative of view parameters assigned to a view output mode from a plurality of view output modes; receive a training mode selection user input indicative of a user selection for an IVD method to be trained from the plurality of methods having an assigned view output mode of the plurality of view output modes.
G06F 3/04815 - Interaction with a metaphor-based environment or interaction object displayed as three-dimensional, e.g. changing the user viewpoint with respect to the environment or object
H04N 13/239 - Image signal generators using stereoscopic image cameras using two 2D image sensors having a relative position equal to or related to the interocular distance
G01N 35/00 - Automatic analysis not limited to methods or materials provided for in any single one of groups ; Handling materials therefor
G01N 35/02 - Automatic analysis not limited to methods or materials provided for in any single one of groups ; Handling materials therefor using a plurality of sample containers moved by a conveyor system past one or more treatment or analysis stations
70.
METHOD FOR TREATING A LIQUID SAMPLE COMPRISING A DIAGNOSTIC ASSAY REAGENT AFTER USE
The present invention relates to a method for treating a liquid sample comprising at least one diagnostic assay reagent after use. The present invention further relates to a tablet, a purified liquid sample, a diagnostic assay reagent, a waste water treatment system, a kit and uses thereof for treating the said liquid sample.
The present disclosure relates generally to methods and systems for detecting, characterizing biomarker expression and morphological analysis in cell samples. The methods allow for the use of automated platforms to stain cells for molecular biomarkers and Romanowsky-type staining for cell morphology analysis. Cells that are prepared according to the disclosed methods can also be used in the diagnosis of certain conditions.
A method for detecting at least one analyte by electrochemical detection, a working electrode of an analyte sensor and an analyte sensor for detecting at least one analyte in a sample by electrochemical detection. The method comprises contacting a fluid sample suspected to comprise the at least one analyte with the surface of an electrode comprising a binding agent capable of binding to the analyte; contacting the fluid sample with a detection agent comprising a further binding agent capable of binding to the analyte and a label, the label comprising a metal nanoparticle with a standard redox potential E° between 0 V and 1.2 V forming a detection complex on the surface of the electrode comprising the binding agent, the detection agent and the analyte precipitating at least a part of the label onto the electrode surface; and detecting the analyte by electrochemical detection.
There is described a method of operating a distribution system. The distribution system comprises a number of carriers wherein the carriers are adapted to carry one or more goods. A transport plane of the distribution system supports the carriers. A control device controls the drive means. During an initialization of the distribution system the control device pre-defines a pattern of safe points on the transport plane, wherein on the safe points a carrier can be placed. After the initialization of the distribution system the control device calculates partial routes for the carriers so that the end position of each partial route is either one of the safe points or has a free path to one of the safe points to be reachable in the next partial route.
G05D 1/02 - Control of position or course in two dimensions
G05B 19/418 - Total factory control, i.e. centrally controlling a plurality of machines, e.g. direct or distributed numerical control (DNC), flexible manufacturing systems (FMS), integrated manufacturing systems (IMS), computer integrated manufacturing (CIM)
74.
A METHOD OF ASSESSING A FEMALE'S RISK OF HAVING PCOS AS WELL AS PRODUCTS AND USES RELATING THERETO
The present invention relates to a method of assessing a female’s risk of having polycystic ovary syndrome (PCOS), a kit for use in assessing a female’s risk of having PCOS, the use of a marker combination in the assessment of a female’s risk of having PCOS, a computer system for use in a method according to the present invention as well as a computer program and a computer-readable storage medium comprising instructions, which when executed by a computer, cause the computer to carry out the method of the present invention.
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
75.
MUTANT REVERSE TRANSCRIPTASE WITH INCREASED THERMAL STABILITY AS WELL AS PRODUCTS, METHODS AND USES INVOLVING THE SAME
The present invention relates to a mutant reverse transcriptase (RT) with increased thermal stability relative to the wildtype, a nucleic acid encoding the mutant RT, a cell comprising the mutant RT or the nucleic acid, a kit comprising the mutant RT, the use of the mutant RT for cDNA synthesis, method for reverse transcription of RNA comprising synthesizing cDNA with the use of the mutant RT and a method for detecting an RNA marker in a sample with the use of the mutant RT.
A laboratory system for analyzing biological samples is presented. The laboratory system comprises a plurality of laboratory instruments configured to receive and identify biological samples and to query a laboratory control unit for a processing order indicative of processing steps to be carried out on the biological sample. The laboratory control unit is configured to validate sequence of queries from the plurality of laboratory instruments against a valid query sequence pattern.
G16H 10/40 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
G01N 35/00 - Automatic analysis not limited to methods or materials provided for in any single one of groups ; Handling materials therefor
A healthcare system for providing medical insights by receiving medically relevant data (MRD) and providing results of medical algorithms using the medically relevant data (MRD), the medically relevant data (MRD) comprising quantitative medical data created based on at least one diagnostic measurement method, wherein the healthcare system comprises two or more medical algorithm modules and a service module, and the functionalities are separated between the medical algorithm modules and the service module.
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
G06F 21/62 - Protecting access to data via a platform, e.g. using keys or access control rules
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
78.
LABORATORY SAMPLE CONTAINER HANDLING APPARATUS, LABORATORY AUTOMATION SYSTEM, AND USE
A laboratory sample container carrier handling apparatus is provided comprising a revolving device, a guiding surface, and a force-applying device, wherein the force-applying device is adapted to apply a force to a laboratory sample container carrier supplied to the revolving device to such an extent that the laboratory sample container carrier is forced against the guiding surface to such an extent that the laboratory sample container carrier rolls off at the guiding surface pushed by the revolving device. A laboratory automation system is also provided comprising such a laboratory sample container carrier handling apparatus and to a use of such a laboratory sample container carrier handling apparatus for handling a laboratory sample container carrier in, in particular such, a laboratory automation system.
G01N 35/02 - Automatic analysis not limited to methods or materials provided for in any single one of groups ; Handling materials therefor using a plurality of sample containers moved by a conveyor system past one or more treatment or analysis stations
A healthcare data management system for managing healthcare data comprising in-vitro diagnostics (IVD) data created using at least one IVD analytical instrument, the healthcare data management system being accessible by a plurality of client devices. The healthcare data management system including: a plurality of healthcare applications each configured to execute one or more operations associated with the healthcare data management system using healthcare data of the healthcare data management system; an intent management system including: an intent registry, storing information about a plurality of intents, the information for each intent including: an intent type identifier, and one or more healthcare applications configured to execute an operation associated with the intent type; and the intent management system further comprising: a healthcare application determination module configured to receive an intent, and to determine, using the intent registry, one or more healthcare applications configured to execute an operation associated with the received intent.
G16H 40/67 - ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
The present invention relates to a method for aiding in the prediction of stroke and/or dementia in a subject, said method comprising a) determining the amount of the biomarker RET (Rearranged during transfection) in a sample from the subject, b) comparing the amount determined in step a) to a reference, and c) aiding in the prediction of stroke and/or dementia. The present invention further relates to a method for aiding in the assessment of the extent of white matter lesions in a subject, a method for aiding in the assessment whether a subject has experienced one or more silent strokes and to a method for aiding in the diagnosis of atrial fibrillation in a subject. Further encompassed by the present invention are the corresponding uses.
The present invention relates to a method for operating a chromatography column comprising (a) providing a first value of a lifetime (first lifetime value) of said chromatography column; (b) performing a chromatographic separation of a sample on said chromatography column; (c) providing a value of a weighted aging factor determined based on at least one aging parameter selected from sample type, sample dilution, and sample volume; and (d) determining a second value of said lifetime (second lifetime value) of said chromatography column based on said first lifetime value and said weighted aging factor. The present invention also relates to further methods, databases, devices, and uses related thereto.
An automated method for performing a leakage test of a fluidic system of an in-vitro diagnostic device as well as an automated in-vitro diagnostic device comprising a controller configured to perform the leakage test. The method comprises activating a pump to provide a fluid from a fluid supply into an electrically conductive probe. The probe is positioned so that a tip of the probe is at a predetermined distance from a reference surface of a reference element. In case of leakage, an electrical signal or change in an electrical signal or a change of the electric or magnetic field between the probe and the reference element is detected in a predetermined measuring time period and at least one maintenance action is triggered.
A distribution system comprising a transport plane configured for distributing a plurality of tube holders, wherein the transport plane comprises at least one transportation area and at least one queue area, wherein the queue area comprises queues of a plurality of different queue types differentiating between tube holder with a sample container, empty tube holder, input queue and output queue; a drive system configured for moving the tube holders on the transport plane; a control system configured to control movement of the tube holders on the transport plane, wherein the control system comprises a routing system configured for calculating routes for the tube holders on the transportation area of the transport plane, wherein the control system comprises a queue manager configured for calculating routes for the tube holders in the queue area considering the different queue types.
G01N 35/00 - Automatic analysis not limited to methods or materials provided for in any single one of groups ; Handling materials therefor
G01N 35/04 - Automatic analysis not limited to methods or materials provided for in any single one of groups ; Handling materials therefor using a plurality of sample containers moved by a conveyor system past one or more treatment or analysis stations - Details of the conveyor system
85.
METHOD AND LABORATORY SYSTEM TO PROVIDE CONTROL SAMPLES FOR VALIDATING A DIAGNOSTICS TEST
A computer implemented method to allocate control samples for validating a diagnostic test within a laboratory system is provided. The laboratory system comprises a storage, a transport system, and at least two analyzers. A total number of control sample aliquots and an aliquot volume for each control sample aliquot is determined based on a validation time schedule. Information is presented for distributing the total control sample volume into the determined total number of control sample aliquots with the determined aliquot volumes. Information is also presented for distributing the control sample aliquots to one or more of the at least two analyzers according to the validation time schedule.
G01N 35/00 - Automatic analysis not limited to methods or materials provided for in any single one of groups ; Handling materials therefor
G01N 35/04 - Automatic analysis not limited to methods or materials provided for in any single one of groups ; Handling materials therefor using a plurality of sample containers moved by a conveyor system past one or more treatment or analysis stations - Details of the conveyor system
The present invention relates to compounds which are suitable to be used in mass spectrometry as well as methods of mass spectrometric determination of analyte molecules using said compounds.
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
C07C 243/34 - Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids with acylating carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of a carbon skeleton further substituted by nitrogen atoms
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
The present invention relates to compounds which are suitable to be used in mass spectrometry as well as methods of mass spectrometric determination of analyte molecules using said compounds.
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 213/74 - Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
The present invention relates to a Corona antigen comprising a Corona nucleocapsid specific amino acid sequence, compositions, and reagent kits comprising the same and methods of producing it. Also encompassed are methods of detecting anti-Corona antibodies in samples using said Corona antigen, and methods of differential diagnosis of an immune response in a patient due to natural Corona infection or due to vaccination against Corona.
A method of assigning an additional test to an existing aliquot sample tube or to a primary sample tube in a laboratory automation system is presented. The laboratory automation system comprises a workflow control unit and analytical laboratory devices in communication with the workflow control unit. The method comprises receiving an additional test request for the existing aliquot sample tube after processing of the existing aliquot sample tube has started, determining if the existing aliquot sample tube is at a retrievable target, waiting until the existing aliquot sample tube reaches a retrievable target if not at a retrievable target, determining if an aliquot timeout has occurred once the existing aliquot sample tube is at a retrievable target, reassigning the addition test to the primary sample tube if an aliquot timeout has occurred, and performing the additional test from the existing aliquot sample tube if no aliquot timeout has occurred.
A method for simulating an in-vitro diagnostic IVD laboratory system (10) comprising an IVD laboratory instrumentation (2) and an IVD laboratory control software module (3) is proposed, together with a respective system (1) and various application thereof. The proposed method comprises:
simulating sample processing within the IVD laboratory instrumentation (2) using a virtual IVD laboratory instrumentation (5) using sample processing data (SPD) provided by the IVD laboratory control software module (3),
operating the IVD laboratory control software module (3) as if it was operating within the IVD laboratory system (10) but wherein sample processing data (SPD) intended for being exchanged between the IVD laboratory control software module (3) and the IVD laboratory instrumentation (2) is instead exchanged between the IVD laboratory control software module (3) and the virtual IVD laboratory instrumentation (5).
The present invention relates to compounds which are suitable to be used in mass spectrometry as well as methods of mass spectrometric determination of analyte molecules using said compounds.
C07D 233/02 - Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
G01N 33/58 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
G01N 33/74 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones
92.
DETECTION METHOD OF CIRCULATING BMP10 (BONE MORPHOGENETIC PROTEIN 10)
The present invention relates to a method for assessing atrial fibrillation in a subject, said method comprising the steps of determining the amount of BMP10 in a sample from the subject, and comparing the amount of BMP10 to a reference amount, whereby atrial fibrillation is to be assessed. Moreover, the present invention relates to a method for diagnosing heart failure based on the determination of BMP 10 in a sample from a subject. Further, the present invention relates to a method for predicting the risk of a subject of hospitalization due to heart failure based on the determination of a BMP10-type peptide in a sample from a subject. The present invention further pertains to antibodies which bind to one or more BMP10-type peptides such as NT-proBMP10.
A distribution system is disclosed. The distribution system comprises a transport plan comprising logical positions, carriers for transporting objects, a drive system to move the carriers on the transport plan between logical positions, a control system configured for controlling the carriers to move on a planned route from a start position to a final destination position on the transport plane via logical positions, wherein the control system comprises a routing system configured for calculating routes for at least two carriers on the transport plane by modeling the transport plane with graphs of nodes, wherein the routing system is configured for calculating the planned routes considering balancing of surface usage of the transport plane, and wherein the routing system is configured for considering temporal blocking of logical positions and/or a considering variable move length and/or considering a variable reservation length.
A racemic hematoxylin formulation is disclosed that includes one or both of a stabilizer compound and an antioxidant. The disclosed composition exhibits sufficient stability to be utilized in an automated staining process. Methods of using and making the stabilized composition also are disclosed.
A distribution system comprising a transport plane for distributing objects and carriers for transporting the objects. A drive system moves the carriers on the transport plane. A control system of the distribution system is configured to control the carriers to move on a planned route from a start position to a final destination position on the transport plane. The control system comprises a routing system configured to calculate the planned route for at least two carriers on the transport plane by modeling the transport plane with nodes and graphs and using a windowed hierarchical cooperative informed search algorithm. The routing system is configured to determine reserved and free time windows for each node. The routing system is configured to assign an individual reservation length to each carrier for the next move on free time windows and assigns an infinite reservation time to the node of a logical position.
A computer implemented method for calibrating a customer mass spectrometry instrument (118) for quantifier-qualifier-ratio check is proposed. The method comprises the following steps:
a) at least one manufacturer-site standardization, wherein a set of samples of a subject and a set of calibrator samples are measured in multiple replicates on a plurality of mass spectrometry instruments (114), wherein each measurement comprises multiple reaction monitoring with quantifier and qualifier transition for analyte and internal standard, wherein at least three adjustment factors are determined from the measurements of the set of samples of a subject and the set of calibrator samples, wherein a first adjustment factor α depends on a difference between analyte and internal standard, wherein a second adjustment factor β depends on a difference between samples of a subject and calibrator samples for analyte quantifier-qualifier-ratio, wherein a third adjustment factor γ depends on a difference between samples of a subject and calibrator samples for the internal standard quantifier-qualifier-ratio;
b) at least one transfer step, wherein the adjustment factors are electronically transferred to a customer mass spectrometry instrument (118);
c) at least one customer-site calibration, wherein the customer-site calibration comprises at least one calibration measurement, wherein a set of calibrator samples is measured on the customer mass spectrometry instrument (118) and quantifier-qualifier-ratios are determined therefrom, wherein target values for quantifier-qualifier-ratios for analyte and for internal standard are set by applying the adjustment factors on the determined quantifier-qualifier-ratios.
The present invention relates to a method for diagnosing a recent paroxysmal atrial fibrillation. The method is based on the determination of the at least one marker selected from the group consisting of a cardiac Troponin, NT-proBNP (N-terminal prohormone of brain natriuretic peptide), hsCRP, IL-6 (Interleukin-6) and IGFBP7 (Insulin like growth factor binding protein 7) in a sample from the subject, and on the comparison of the, thus, determined amount(s) with a reference amount (reference amounts). Further, the present invention relates to a method for identifying a subject being treatable with anticoagulation therapy. Further envisaged are systems, reagents and kits used in performing the methods disclosed herein.
A method of routing test samples during periods of laboratory disruption in a laboratory system is disclosed. The method comprises determining that a laboratory device is unavailable, masking a target laboratory device so that test samples are not sent to the target laboratory device and test samples cannot be retrieved from the target laboratory device, rerouting test samples from the target laboratory device to a buffer, calculating a new laboratory workflow after the laboratory device becomes available, unmasking the target laboratory device after the new laboratory workflow is calculated, and retrieving the test samples from buffer and sending the test samples to the target laboratory device.
A method for operating a laboratory automation system, having: a control device and a transport system with carriers and a first empty carrier queue provided with a first fixed number of queue spaces, each assignable an empty carrier; the method comprising: providing additional queue spaces, each assignable an empty carrier, assigning a first number of additional queue spaces from the additional queue spaces to the first empty carrier queue, operating the first empty carrier queue with the first fixed number of queue spaces plus the first number of additional queue spaces, assigning, in response to receiving operation data in the control device, a second number of additional queue spaces from the additional queue spaces to the first empty carrier queue and operating the first empty carrier queue with the first fixed number of queue spaces plus the second number of additional queue spaces. Further, a laboratory automation system is provided.
The present disclosure relates to specific binding agents binding to different PIVKA-II forms as compared to antibodies known so far in the art. The present disclosure also relates to methods of using the specific binding agents to detect the presence of PIVKA-II.
patents
